Clinical Trials Tracker
What's published, what's pending, and when approval is expected.
A living tracker of every retatrutide clinical trial from Phase 1 through the TRIUMPH Phase 3 program, plus the FDA approval timeline. Updated as new readouts are published.
Related topic hubs
- Retatrutide — Retatrutide drug overview
- Conditions — Trials by indication
- Drugs — Other drugs in active trials
The program at a glance
| Phase | Trial | N | Duration | Status | Headline |
|---|---|---|---|---|---|
| 1 | NCT04143802 (T2D) | — | 12 wks | Complete | -8.5 kg; -0.9% HbA1c |
| 2 | NCT04881760 (obesity) | 338 | 48 wks | Complete | -24.2% at 12 mg |
| 2 | NCT04867785 (T2D) | 281 | 36 wks | Complete | -2.02% HbA1c, -16.94% weight |
| 2 | MASLD sub-study | — | — | Complete | 81–86% liver fat reduction |
| 3 | TRIUMPH-1 (obesity) | 2,339 | 80 wks | Complete | Pivotal. -28.3% at 12 mg; reported May 2026. |
| 3 | TRIUMPH-2 (obesity + T2D) | — | — | Active | Readout expected 2026 |
| 3 | TRIUMPH-3 (CV disease) | — | — | Active | Readout expected 2026 |
| 3 | TRIUMPH-4 (knee OA) | 445 | 68 wks | Complete | -28.7%; 74–76% pain reduction |
| 3 | TRIUMPH-5 (CV / renal) | — | Multi-year | Recruiting | MACE endpoints |
| 3b | TRIUMPH-6 (maintenance) | 643 | — | Active | Closed to new enrollment |
Total TRIUMPH Phase 3 enrollment: approximately 5,800 participants. See the full clinical trials deep dive for each trial's design, endpoints, and citations.
2026 readout calendar
- Reported. TRIUMPH-4 (Dec 2025), TRANSCEND-T2D-1 (Mar 2026), and the pivotal TRIUMPH-1 (May 21, 2026) have all read out.
- Still expected in 2026. TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (CV disease) readouts remain outstanding.
- 2027+. TRIUMPH-5 (CV/renal outcomes) is a multi-year trial; earliest interim reads from 2027+.
How to participate
The primary enrolling trial is TRIUMPH-5 (cardiovascular / renal outcomes). For enrollment process and eligibility:
FDA timeline
The FDA filing trigger was the TRIUMPH-1 primary readout, which reported in May 2026. Retatrutide remains investigational; no BLA submission or FDA decision date has been confirmed by Lilly or the FDA. See the FDA approval timeline article for the full scenario analysis.
All trials & fda articles
4 articles
How to Sign Up for a Retatrutide Clinical Trial
The only way to access retatrutide in 2026 is through clinical trials. Here's how to find and enroll in a TRIUMPH trial.
Updated February 2026
Retatrutide FDA Approval Timeline 2026-2028: Filing & Status
TRIUMPH-1, the pivotal obesity trial, has reported. Projected FDA filing 2026-27, approval 2027-28. Live timeline.
Updated July 2026
Retatrutide Phase 3 Trials 2026: TRIUMPH & TRANSCEND-T2D Tracker
Living tracker of every retatrutide trial — TRIUMPH-1/3/4/5, TRANSCEND-T2D-1/2, and SYNERGY-OUTCOMES Phase 3 readouts.
Updated July 2026
Retatrutide Results: Before and After — What the Data Actually Shows
No real before/after photos exist. Here's what the clinical trial data shows: 28.7% average weight loss at 68 weeks, month-by-month breakdown.
Updated February 2026